Patient Input Requested for Merck Interferon-Free Combo

HepCBC is seeking individual patient input for our submission to the federal government for an INTERFERON-FREE, ONE PILL/DAY drug combo, shown to be effective for genotypes 1, 3, 4, and 6, Merck Pharmaceutical's elbasvir + grazoprevir (± ribavirin). The treatment's success (96% - 100% SVR12) has been confirmed in trials including people considered 'hard to treat' including those who had failed previous treatment (including simeprevir, boceprevir, and telap

View all hepatitis C drug Patient Group input from HepCBC

We are asking for patients to give us input about a new treatment for genotype 4 patients. Are you curious how we use this data?  Want to see what HepCBC tells BC Pharmacare, or the federal drug review agencies about patients' opinions of new hepatitis C treatments? Exactly what did HepCBC tell them about Daklinza (daclatasvir), Holkira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir), Harvoni (sofosbuvir+ledipasvir), Sovaldi (sofusbovir), Sunpr...

Patient Input Requested for AbbVie 2D-GT4 Combo

HepCBC is seeking individual patient input for our submission to the federal government for the first INTERFERON-FREE drug combo for GENOTYPE 4, AbbVie's "2D-GT4".ADD YOUR VOICE! We will be accepting input from anyone affected by hepatitis C (ALL GENOTYPES, not only Genotype 4) between Friday, Sept. 11 and midnight on Thursday, Sept. 25, 2015 through this confidential online form: PATIENT INPUT FORM for AbbVie 2D-GT4 Free WEBINAR about AbbVie 2D-GT4 availa